Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in treatment‐related death compared with non‐irinotecan‐containing regimens (low certainty).
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan‐based regimens probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).